Products - Children and young people | Topic

Showing 21 products

Date | Sort by Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter
New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Risdiplam for treating spinal muscular atrophy in children and adults [ID1631]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
21 July 2021
Babies, children and young people's experience of healthcare
Status:
In development
Programme:
NICE guideline
Expected publication date:
25 August 2021
Looked-after children and young people
Status:
In development | In consultation
Programme:
NICE guideline
Consultation end date:
15 June 2021
Expected publication date:
20 October 2021
Secukinumab for treating plaque psoriasis in children and young people [ID1669]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
20 October 2021
Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and education
Status:
In development
Programme:
NICE guideline
Expected publication date:
19 January 2022
Epilepsies in children, young people and adults
Status:
In development
Programme:
NICE guideline
Expected publication date:
9 March 2022
Self harm: assessment, management and preventing recurrence
Status:
In development
Programme:
NICE guideline
Expected publication date:
18 May 2022
Social, emotional and mental wellbeing in primary and secondary education
Status:
In development
Programme:
NICE guideline
Expected publication date:
6 July 2022
Maternal and child nutrition
Status:
In development
Programme:
NICE guideline
Expected publication date:
22 November 2023
Otitis media with effusion in under 12s: surgery
Status:
In development
Programme:
NICE guideline
Expected publication date:
7 December 2023
KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 ID1336
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Fenfluramine for treating seizures associated with Dravet syndrome [ID1109]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy ID1587
Status:
Proposed
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Selumetinib for treating inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 years and over [ID1590]
Status:
Proposed
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged under 18 with non-malignant diseases [ID3745]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sodium thiosulfate for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy [ID1001]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]
Status:
Proposed
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]
Status:
Proposed
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Leriglitazone for treating X-linked andrenoleukodystrophy [ID 3903]
Status:
Proposed
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Children and young people Products

Filter

Product type
1 selected

Guidance programme

Status

New and updated
1 selected

Showing 21 products

Risdiplam for treating spinal muscular atrophy in children and adults [ID1631]

Babies, children and young people's experience of healthcare

Looked-after children and young people

Secukinumab for treating plaque psoriasis in children and young people [ID1669]

Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and education

Epilepsies in children, young people and adults

Self harm: assessment, management and preventing recurrence

Social, emotional and mental wellbeing in primary and secondary education

Maternal and child nutrition

Otitis media with effusion in under 12s: surgery

KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 ID1336

Fenfluramine for treating seizures associated with Dravet syndrome [ID1109]

Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]

Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]

Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy ID1587

Selumetinib for treating inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 years and over [ID1590]

Treosulfan with fludarabine before allogeneic stem cell transplant for people aged under 18 with non-malignant diseases [ID3745]

Sodium thiosulfate for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy [ID1001]

Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]

Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]

Leriglitazone for treating X-linked andrenoleukodystrophy [ID 3903]

Children and young people Products

Filter

Product type1 selected

Guidance programme

Status

New and updated1 selected

Showing 21 products

Product type
1 selected

New and updated
1 selected